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1Pulmonary hypertension (PH) frequently coexists with severe aortic stenosis (AS) and confers a worse prog-
nosis.1,2 Transcatheter aortic valve implantation (TAVI) is 
an alternative therapeutic modality to surgical aortic valve 
replacement (SAVR) for patients with symptomatic severe 
AS who are either inoperable or high risk for conventional 
SAVR.3–5 Patient selection for TAVI relies on clinical and 
anatomic factors, and risk assessment is a critical component 
of the procedural planning.6 Previous studies have shown PH 
to be a predictor of mortality after TAVI.7–11 However, studies 
to date have focused mainly on PH severity rather than hemo-
dynamic presentation and used noninvasive measurements of 
pulmonary artery systolic pressure (PASP), which correlate 
only modestly with invasive measurements.12 According to 
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guidelines, right heart catheterization (RHC) remains the gold 
standard for the accurate diagnosis of PH.13
PH is a heterogeneous entity, and according to the updated 
clinical classification of PH (5th World Symposium on PH, 
Nice, 2013), 5 groups are recognized (Figure 1).14,15 Group 2 or 
postcapillary PH is because of left-sided heart disease and can 
be distinguished from the other 4 noncardiogenic PH groups 
(collectively categorized as precapillary PH) according to 
whether left ventricular (LV) filling pressures are elevated or 
not. Moreover, left-sided PH can be further stratified into iso-
lated (reversible) and combined postcapillary and precapillary 
(±reversible) subgroups depending on whether the diastolic 
pressure difference (DPD) is normal or elevated (Figure 1).15 
Whether PH hemodynamic presentation may help further risk 
stratify patients undergoing TAVI is unknown. We therefore 
aimed to assess the effect of PH hemodynamic presentation 
on clinical outcomes after TAVI using patients without PH as 
a reference group.
Methods
Patient Population
We performed an analysis of prospectively collected data that included 
all patients who underwent TAVI at our institution between August 
2007 and December 2012. Patients were deemed high risk or inoper-
able for conventional SAVR by a multidisciplinary heart team. Patient 
flow is shown in Figure 2. Only patients with severe symptomatic AS 
(indexed aortic valve area, <0.6 cm2/m2) undergoing a preprocedural 
RHC were considered for inclusion. Of 606 consecutive patients un-
dergoing TAVI during the inclusion period, 471 (78%) patients had 
a preprocedural RHC. The 135 (22%) patients without a RHC were 
excluded from this analysis. A further 38 patients were excluded for 
the reasons shown in Figure 2. The remaining 433 patients with severe 
symptomatic native valve AS were dichotomized according to whether 
PH (invasive mean pulmonary artery pressure [mPAP], ≥25 mm Hg) 
was present (n=325) or not (n=108). Patients with PH were further 
dichotomized into precapillary (LV end-diastolic pressure [LVEDP], 
≤15 mm Hg; n=56) and postcapillary (LVEDP, >15 mm Hg; n=269) 
subtypes. Finally, patients with postcapillary PH were dichotomized 
into isolated postcapillary (n=220) and combined postcapillary and 
precapillary (n=49) subtypes based on whether the DPD was normal 
(<7 mm Hg) or elevated (≥7 mm Hg). DPD was calculated as diastolic 
PAP minus LVEDP.15 In 8 patients, the aortic valve was not crossed 
and the mean pulmonary arterial wedge pressure was substituted for 
the LVEDP for group categorization in these patients. This study com-
plies with the Declaration of Helsinki, was approved by the local eth-
ics committee, and all patients provided informed written consent.
Right and Left Heart Catheterization
All included patients underwent diagnostic coronary angiography and 
complete left and RHC for hemodynamic assessment before TAVI as 
previously described.16 Pulmonary artery and intracardiac pressures 
were measured and recorded using fluid-filled catheters connected to 
pressure transducers.
Cardiac output (CO) was determined using the modified Fick 
method with estimated oxygen consumption (VO2) as previously 
described and was indexed to body surface area to calculate the 
cardiac index.16 Stroke volume was calculated as CO/heart rate and 
was indexed to body surface area to calculate the stroke volume in-
dex. AS severity and arterial and global afterload were calculated as 
WHAT IS KNOWN
•	Pulmonary hypertension (PH) as assessed by non-
invasive echocardiography frequently coexists with 
severe aortic stenosis and confers a worse progno-
sis among patients undergoing conventional surgical 
aortic valve replacement.
•	PH is a heterogeneous entity, and invasive evaluation 
of pulmonary artery pressures is the gold standard 
method to define PH and assess PH severity.
WHAT THE STUDY ADDS
•	This article examined the effect of PH hemodynamic 
presentation on clinical outcomes after transcatheter 
aortic valve implantation using data derived from in-
vasive evaluation according to the new updated PH 
hemodynamic definitions.
•	Patients with precapillary PH and combined post-
capillary and precapillary PH have the worst out-
comes after transcatheter aortic valve implantation, 
whereas patients with isolated postcapillary PH have 
outcomes similar to patients with no pulmonary PH.
Figure 1. Hemodynamic definitions of pulmonary 
hypertension (PH) according to the Proceedings of 
the 5th World Symposium on Pulmonary Hyperten-
sion.14,15 CO indicates cardiac output; DPD, dia-
stolic pressure difference; LVEDP, left ventricular 
end-diastolic pressure; PA, pulmonary artery; and 
PAWP, pulmonary arterial wedge pressure.
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previously described.16 LVEDP was measured at the Z-point, which 
is identified as the point at which the slope of the ventricular pres-
sure upstroke changes on the LV pressure tracing, which corresponds 
to the R wave on the electrocardiographic tracing. Measurements of 
LVEDP were made at the end of expiration.
Pulmonary vascular resistance was calculated as transpul-
monary gradient/CO (Woods units) and transpulmonary gradi-
ent×80/CO (dynes s per cm5). Pulmonary arterial compliance was 
calculated as the stroke volume/(sPAP−dPAP), sPAP indicating 
the systolic PA pressure and dPAP diastolic PA pressure.17 Right 
ventricular stroke work index was calculated as stroke volume 
index×(mPAP−mRAP)×0.0136, with mRAP indicating mean right 
atrial pressure.18 A DPD of ≥7 mm Hg is associated with more ad-
vanced pulmonary vascular remodeling.19
Echocardiography
Transthoracic 2-dimensional echocardiography was performed at 
baseline using commercially available ultrasound systems (iE33, 
Philips Medical systems). Acquired images were transferred to a 
workstation for offline analysis (Syngo Dynamics Workplace, ver-
sion 9.5, Siemens Medical Solutions, Inc). LV geometric assessment 
was performed as recommended, and LV mass was calculated using 
the Devereux formula and indexed to body surface area.20 LV ejection 
fraction (LVEF) was calculated according to the Simpsons method. 
Mitral, aortic, and tricuspid valve regurgitation were evaluated using 
spectral and color-Doppler images and graded as trivial, mild, moder-
ate, and severe, as recommended.21 Right ventricular systolic function 
was assessed using tricuspid annular plane systolic excursion and the 
pulsed Doppler peak velocity at the annulus as previously described.22 
Aortic valve area was assessed using the continuity equation and in-
dexed to the body surface area.23 The mean transaortic valve gradient 
was measured using continuous wave Doppler in the apical 5-cham-
ber view.23 Maximal tricuspid regurgitant jet velocity combined with 
central venous pressure measured using the inferior caval vein respi-
ratory variation was used to calculate the PASP.
Transcatheter Aortic Valve Implantation
TAVI was performed as previously described.24 Vascular access was 
transfemoral using the Edwards SAPIEN/XT (Edwards Lifesciences, 
Irvine, CA) or the Medtronic CoreValve Revalving System 
(Medtronic Inc., Minneapolis, MN), transapical for the Edwards 
SAPIEN/XT or self-expanding Symetis ACURATE TA valve 
(Symetis Inc, Switzerland) or transsubclavian using the Medtronic 
CoreValve Revalving System.
Clinical Follow-Up
Adverse events were assessed in hospital, and regular clinical follow-
up was performed at 1, 6, and 12 months by means of a clinical visit 
or standardized telephone interview. All suspected events were adju-
dicated by a clinical event committee comprising a cardiac surgeon 
and an interventional cardiologist. Baseline clinical and procedural 
characteristics and all follow-up data were entered into a dedicated 
database, held at an academic clinical trials unit (CTU Bern, Bern 
University Hospital, Bern, Switzerland) responsible for central data 
audits and maintenance of the database.
Study End Points
Clinical end points were defined according to the criteria of the 
Valve Academic Research Consortium-2 consensus document.25 
Primary end point was all-cause mortality at 1 year. Secondary end 
points included cardiovascular death, major adverse cardiovascular 
and cerebrovascular events (composite of all-cause mortality, major 
stroke, and myocardial infarction [MI]), and the composite of death 
and major stroke at 30 days and 1 year. Other end points included 
cerebrovascular events (major stroke, minor stroke, and transient 
ischemic attack) and MI at 30 days and 1 year. In addition, bleeding 
(life-threatening and major), acute renal failure, vascular complica-
tions (major and minor), and rates of pacemaker implantation were 
assessed at 30 days. New York Heart Association (NYHA) functional 
class status was assessed at baseline and 1-year follow-up. LVEF, 
right ventricular function, and PASP were assessed on discharge 
echocardiography.
Statistics
All patients included into this study were divided into 4 groups as 
follows: (1) no PH (n=108; mPAP, <25 mm Hg; reference group); 
(2) precapillary PH (n=56; mPAP, ≥25 mm Hg; LVEDP, ≤15 mm Hg; 
Figure 2. Patient flow. DPD indicates diastolic pressure difference; LVEDP, left ventricular end-diastolic pressure; PA, pulmonary artery pres-
sure; PH, pulmonary hypertension; and TAVI, transcatheter aortic valve implantation. *In 8 patients, the aortic valve was not crossed during 
preprocedural right heart catheterization, and the pulmonary arterial wedge pressure was used for group categorization in these patients.
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precapillary group); (3) postcapillary isolated PH (n=220; mPAP, 
≥25 mm Hg; LVEDP, >15 mm Hg; DPD, <7 mm Hg; isolated group); 
(4) combined postcapillary and precapillary PH (n=49; mPAP, ≥25 
mm Hg; LVEDP, >15 mm Hg; DPD, ≥7 mm Hg; combined group).
Discrete data were summarized as counts with percentages with 
P values from χ2 or Fisher exact tests, whereas continuous data were 
presented as means±SD with P values from 1-way ANOVAs when 
normally distributed or medians (interquartile range) for skewed data 
using P values from Kruskal–Wallis tests (Tables 1–4). Counts and 
incidence rates of clinical outcomes at 30-day and 1-year follow-
up were computed from Kaplan–Meier life tables for the 4 groups 
(Table 5; Table I in the Data Supplement). Cox regression was used 
to compute hazard ratios (HRs) of outcomes (and 95% CI). The pro-
portional hazards assumption was verified for Cox models. Adjusted 
HRs were estimated from multivariable Cox regressions, adjusting 
for age, sex, body mass index, diabetes mellitus, previous coronary 
artery bypass graft surgery, peripheral vascular disease, previous MI, 
coronary artery disease, LVEF ≤30%, and chronic obstructive pul-
monary disease (Table 6). These variables were selected as they are 
well known to be associated with adverse outcomes after TAVI. No 
adjustments were made for multiple comparisons. Changes in left and 
right ventricular function and PASPs after TAVI (difference between 
discharge and baseline) were analyzed overall and within each group 
using a linear mixed model taking into account the within-patient 
correlation (Table 7). Two sided P values of <0.05 were considered 
as statistically significant. All analyses were performed using Stata 
version 13.0.
Results
Baseline Characteristics
Patient flow is shown in Figure 2. Mean age was 82.4±5.3 
years. When compared with isolated and no PH groups, 
patients with combined and precapillary PH had a significantly 
higher prevalence of atrial fibrillation (19% versus 15% versus 
53% versus 39%; P<0.001, respectively) and had significantly 
higher surgical risk scores (Society for Thoracic Surgeons 
score, 7.2±5.9% versus 5.9±3.3% versus 7.0±3.6% versus 
8.2±5.6%; P=0.011 and logistic EuroSCORE 24.1±13.8% 
versus 18.3±11.0% versus 31.0±15.8% versus 23.9±13.2%; 
P<0.001, respectively). All 3 PH groups were significantly 
more symptomatic according to NYHA functional status 
when compared with patients with no PH. Significantly more 
patients with precapillary PH were taking oral anticoagula-
tion, angiotensin-converting enzyme/angiotensinogen recep-
tor II blockers, and calcium channel blockers when compared 
with other groups (Table 1).
Echocardiographic and Invasive Hemodynamic 
Characteristics
Echocardiographic and invasive hemodynamic data are sum-
marized in Tables 2 and 3, respectively. Both isolated and 
combined PH patients had smaller aortic valve areas when 
compared with patients with no PH. Patients with combined 
PH had a lower LVEF when compared with other groups. 
Both combined and precapillary PH patients had worse right 
ventricular function and a higher prevalence of moderate to 
severe tricuspid regurgitation. Patients with combined PH had 
a higher prevalence of moderate to severe mitral regurgita-
tion when compared with patients with no PH. RHC was per-
formed a median of 20 days (interquartile range, 8–39 days) 
before TAVI. When compared with no PH groups, combined 
and precapillary PH patients had lower COs, cardiac indices, 
faster heart rates, higher pulmonary vascular resistances, lower 
pulmonary arterial compliances, and higher transpulmonic 
gradients. Patients with combined PH had a worse severity 
of PH when compared with both other PH groups, whereas 
patients with isolated PH had a significantly worse severity of 
PH when compared with precapillary patients.
Procedural Characteristics
Procedural data are summarized in Table 4. Most patients 
underwent TAVI via the transfemoral route with 14% of 
patients undergoing either staged or concomitant percutane-
ous coronary intervention.
Clinical Outcomes
One-year clinical follow-up was completed for 415 of 433 
(96%) patients. Unadjusted and adjusted clinical events at 
1-year follow-up are presented in Tables 5 and 6, respec-
tively. Although there were no significant differences in all-
cause mortality between groups at 30 days, a trend toward a 
higher rate of cardiac mortality was observed among patients 
with precapillary PH at 30 days when compared with those 
without PH (unadjusted HR, 5.11; 95% confidence interval 
(CI), 0.99–26.35), but this did not reach statistical signifi-
cance (P=0.051). There were no statistically significant differ-
ences in other clinical end points at 30 days between the study 
groups (Table I in the Data Supplement).
Mortality over time ≤12 months for all-cause mortality 
and cardiac death among patients stratified according to the 
presence or absence of PH is shown in Figure 3 and stratified 
according to the 4 hemodynamic subgroups in Figure 4.
When compared with patients without PH, patients with 
PH had a statistically significant higher overall mortality 
rate at 1 year (19.7% versus 10.3%; unadjusted HR, 2.03; 
95% CI, 1.07–3.85; P=0.030; Figure 3; Table II in the Data 
Supplement). After adjustment, PH remained a predictor for 
all-cause mortality at 1 year (adjusted HR, 1.95; 95% CI, 
1.01–3.76; P=0.046; Table III in the Data Supplement).
When stratified according to the 4 hemodynamic sub-
groups, patients with precapillary PH had a higher rate of death 
(10.3% versus 21.7%; unadjusted HR, 2.30; 95% CI, 1.02–5.22; 
P=0.046) compared with patients without PH, which was driven 
mainly by cardiac death (unadjusted HR, 3.00; 95% CI, 1.14–
7.88; P=0.026) at 1 year. After adjustment, however, differences 
in death (adjusted HR, 1.90; 95% CI, 0.83–4.35; P=0.13) and 
cardiac death (adjusted HR, 2.25; 95% CI, 0.85–5.97; P=0.11) 
were no longer significant. No statistically significant differences 
in death (adjusted HR, 1.75; 95% CI, 0.88–3.49; P=0.11) or car-
diac death (adjusted HR, 1.55; 95% CI, 0.65–3.71; P=0.33) were 
observed between no PH and isolated PH groups. When com-
pared with patients with no PH, those with combined PH had a 
higher rate of death (10.3% versus 29.0%; unadjusted HR, 3.15; 
95% CI, 1.43–6.93; P=0.004) driven predominantly by cardiac 
death (unadjusted HR, 3.84; 95% CI, 1.49–9.91; P=0.005) at 1 
year. After adjustment for age, sex, body mass index, diabetes 
mellitus, previous coronary artery bypass graft, previous MI, 
peripheral vascular disease, coronary artery disease, chronic 
obstructive pulmonary disease, and LVEF ≤30%, combined PH 
remained a strong predictor for death (adjusted HR, 3.28; 95% 
CI, 1.43–7.53; P=0.005) and cardiac death (adjusted HR, 3.81; 
95% CI, 1.40–10.36; P=0.009) at 1 year.
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Table 1. Baseline Characteristics
No PH 
n=108
PH
P Value
Precapillary 
n=56
Isolated 
n=220
Combined 
n=49
Age, y 81.7±5.4 82.9±4.1 82.6±5.2 82.2±6.2 0.48
Female, sex, n (%) 48 (44) 33 (59) 124 (56)† 32 (65) 0.059
Height, cm 165.2±8.0 166.5±7.8 164.4±8.6 163.7±7.2 0.27
Weight, kg 72.6±15.5 73.9±17.1 71.2±14.5 70.0±13.9 0.50
Body mass index, kg/m² 26.5±5.1 26.6±5.8 26.3±5.0 26.2±5.1 0.95
Body surface area, m² 1.8±0.2 1.9±0.2 1.8±0.2 1.8±0.2 0.42
Cardiac risk factors
  Diabetes mellitus, n (%) 31 (29) 23 (41) 58 (26) 14 (29) 0.20
  Hypercholesterolemia, n (%) 75 (69) 34 (61) 145 (66) 31 (63) 0.70
  Hypertension, n (%) 95 (88) 45 (80) 189 (86) 40 (82) 0.52
  Current smoker, n (%) 11 (12) 6 (11) 15 (7) 6 (15) 0.36
Past medical history
  Coronary artery disease, n (%) 63 (58) 35 (63) 144 (65) 28 (57) 0.53
  Multivessel disease, n (%) 27 (69) 14 (61) 54 (70) 7 (47) 0.32
  Previous myocardial infarction, n (%) 17 (16) 9 (16) 34 (15) 5 (10) 0.80
  Previous coronary artery bypass graft, n (%) 10 (9) 4 (7) 13 (6) 3 (6) 0.73
  Previous percutaneous coronary intervention, n (%) 35 (32) 18 (32) 58 (26) 8 (16) 0.16
  Previous stroke, n (%) 5 (5) 2 (4) 7 (3) 2 (4) 0.93
  Peripheral vascular disease, n (%) 24 (22) 13 (23) 37 (17) 14 (29) 0.24
  Chronic obstructive pulmonary disease, n (%) 18 (17) 14 (25) 34 (15) 10 (20) 0.38
  Renal failure (GFR<60 mL/min per 1.73 m2) 74 (81) 37 (80) 148 (84) 37 (84) 0.93
Baseline cardiac rhythm
  Atrial fibrillation, n (%) 8 (15) 19 (53)* 21 (19) 12 (39)‡ <0.001
Symptoms
  Syncope, n (%) 20 (19) 9 (16) 28 (13) 3 (6) 0.18
  NYHA functional class
   NYHA III/IV, n (%) 60 (59) 44 (80)* 157 (76)† 40 (83)‡ 0.002
  CCS angina status
   CCS III/IV, n (%) 19 (18) 9 (16) 31 (14) 5 (10) 0.65
Risk assessment
  Logistic EuroScore (%) 15.4 (10.0–25.0) 22.5 (12.1–32.5)* 22.0 (13.4–31.6)† 29.0 (17.3–43.9)‡ <0.001
  STS score (%) 4.7 (3.5–7.9) 6.8 (4.3–9.8)* 5.7 (4.0–8.0)† 6.0 (4.5–9.1)‡ 0.016
Medications
  Aspirin, n (%) 75 (70) 31 (55) 147 (67) 27 (56) 0.14
  Clopidogrel, n (%) 29 (27) 9 (16) 42 (19) 5 (10) 0.08
  Oral anticoagulation, n (%) 21 (20) 28 (50)* 46 (21) 17 (35)‡ <0.001
  Diuretic, n (%) 72 (67) 45 (80) 153 (70) 38 (79) 0.19
  β-blocker, n (%) 51 (48) 30 (54) 121 (55) 26 (54) 0.64
  ACEi/ARB, n (%) 38 (36) 34 (61)* 78 (36) 18 (38) 0.005
  Ca channel blocker, n (%) 21 (20) 9 (16) 46 (21) 2 (4)‡ 0.049
  Statin, n (%) 58 (54) 24 (43) 109 (50) 19 (40) 0.29
Laboratory values
  Brain natriuretic peptide, pg/mL 174.5 (106.0–358.3) 256.0 (113.5–534.5) 358.0 (158.5–876.5)† 624.0 (274.0–1510.0)‡ <0.001
Depicted are mean±SD with P values from ANOVAs or counts (%) with P values from χ2 tests. For skewed variables depicted are median (interquartile range) with 
P values from Kruskal–Wallis test. Body surface area is computed using Haycock formula. GFR is computed using Cockroft–Gault formula. ACEi/ARB indicates 
angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CCS, Canadian Cardiovascular Society; GFR, Glomerular filtration rate; NYHA, New York Heart 
Association; PH, pulmonary hypertension; and STS, Society of Thoracic Surgeons.
*P<0.05, no PH vs precapillary PH.
†P<0.05, no PH vs isolated PH.
‡P<0.05, no PH vs combined PH.
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Both precapillary (HR, 2.24; 95% CI, 1.05–4.76; P=0.04) 
and combined PH (HR, 2.86; 95% CI, 1.36–6.01; P=0.006) 
had a higher incidence of the composite end point of death or 
major stroke at 1 year. After adjustment, only combined PH 
remained as a predictor or death or major stroke (adjusted HR, 
3.10; 95% CI, 1.41–6.79; P=0.005). Combined PH was also a 
predictor of the composite end point of death, major stroke, or 
MI at 1 year (adjusted HR, 3.13; 95% CI, 1.49–6.58; P=0.003) 
after adjustment. No statistically significant differences in the 
other end points were observed at 1 year.
NYHA Functional Class Improvement
NYHA functional class improvement at baseline and 12 
months is shown in Figure 5. At 12-month follow-up, 13.2% 
and 10.0% of patients with precapillary PH and combined 
PH remained in NYHA>II functional class when compared 
Table 2. Echocardiographic Characteristics
No PH 
n=108
PH
P Value
Precapillary 
n=56
Isolated 
n=220
Combined 
n=49
Aortic stenosis severity
  Aortic valve area, cm2 0.65±0.22 0.62±0.26 0.57±0.22† 0.54±0.20‡ 0.008
  Indexed aortic valve area, cm2/m2 0.36±0.12 0.33±0.14 0.32±0.12† 0.31±0.12‡ 0.034
  Aortic maximal velocity, cm/s 3.82±1.11 3.78±0.88 4.08±0.82 3.66±0.75 0.15
  Mean gradient, mm Hg 42.3±16.9 40.1±17.1 44.1±17.3 40.0±15.9 0.26
  Peak gradient, mm Hg 68.0±25.2 59.4±23.5 71.9±27.2 60.2±23.1 0.019
LV geometry and 2D measurements
  LV end-systolic diameter, mm 32.9±10.4 31.6±11.5 33.2±11.9 39.0±13.1 0.20
  LV end-diastolic diameter, mm 48.9±9.8 46.0±9.8 48.0±10.6 50.2±9.0 0.63
  LV mass index, g/m2 142.6±43.7 149.6±60.8 150.7±42.0 143.3±39.0 0.80
LV systolic function
  LV ejection fraction, % 56.9±13.1 54.6±13.4 51.2±15.4† 44.2±15.9‡ <0.001
RV systolic function
  TAPSE, mm 19.2±4.6 16.4±4.8 18.9±5.6 15.4±4.8‡ 0.016
  DTI, cm/s 12.2±2.8 10.9±4.2 11.7±2.7 10.3±2.8‡ 0.09
Associated valvular abnormality
  Aortic regurgitation
   None 22 (23%) 15 (28%) 46 (23%) 8 (16%) 0.36
   Mild 67 (69%) 34 (64%) 130 (66%) 34 (69%)
   Moderate 8 (8%) 4 (8%) 21 (11%) 6 (12%)
   Severe 0 (0%) 0 (0%) 0 (0%) 1 (2%)
  Mitral regurgitation … … … …‡ <0.001
   None 8 (8%) 2 (4%) 15 (7%) 5 (10%)
   Mild 77 (76%) 39 (70%) 145 (69%) 18 (37%)
   Moderate 15 (15%) 14 (25%) 46 (22%) 20 (41%)
   Severe 1 (1%) 1 (2%) 4 (2%) 6 (12%)
  Tricuspid regurgitation … …* … …‡ <0.001
   None 21 (22%) 8 (16%) 46 (24%) 9 (19%)
   Mild 68 (71%) 25 (49%) 118 (63%) 26 (55%)
   Moderate 7 (7%) 17 (33%) 22 (12%) 9 (19%)
   Severe 0 (0%) 1 (2%) 2 (1%) 3 (6%)
Right sided hemodynamics
  RV–RA gradient, mm Hg 31.1±8.9 40.5±10.3* 41.1±12.2† 48.2±12.6‡ <0.001
  Central venous pressure, mm Hg 7.9±3.9 10.1±8.8 8.9±3.7 10.3±4.5‡ 0.07
  Pulmonary artery systolic pressure, mm Hg 39.0±10.9 50.7±15.8* 50.2±13.6† 58.4±14.4‡ <0.001
Depicted are mean±SD with P values from ANOVAs or counts (%) with P values from Fisher exact tests. DTI indicates pulse Doppler peak velocity at the annulus; LV, 
left ventricle; PH, pulmonary hypertension; RA, right atrial; RV, right ventricle; and TAPSE, tricuspid annular plane systolic excursion.
*P<0.05, no PH vs precapillary PH.
†P<0.05, no PH vs isolated PH.
‡P<0.05, no PH vs combined PH.
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with 9.0% and 7.9% of patients with isolated and no PH, 
respectively.
Echocardiographic Outcomes
Acute changes in biventricular function and PASPs are shown 
in Table 7. Significant improvements in right ventricular func-
tion and PASPs were observed in both isolated and combined 
PH groups. No statistically significant improvements in right 
ventricular function or PASP were observed in the precapil-
lary PH group (Figure 6).
Discussion
This study demonstrates that PH hemodynamic presentation 
affects procedural outcome of patients undergoing TAVI. We 
found that when compared with patients without PH, 1-year 
mortality was higher in both precapillary and combined PH 
patients but not in patients with isolated PH. These findings 
have relevant clinical implications because PH is frequent 
in patients undergoing TAVI with a prevalence reported in 
previous studies between 10% and 42%.9,26–30 In our study, 
3 quarters of patients (75%) with symptomatic severe AS 
Table 3. Invasive Hemodynamic Characteristics
No PH 
n=108
PH
P Value
Precapillary 
n=56
Isolated 
n=220
Combined 
n=49
Aortic stenosis severity
  Aortic valve area, cm2 0.63±0.23 0.57±0.26 0.55±0.25† 0.51±0.20‡ 0.009
  Indexed aortic valve area, cm2/m2 0.35±0.13 0.32±0.15 0.31±0.14† 0.29±0.12‡ 0.014
  Peak-to-peak gradient, mm Hg 48.2±23.1 46.1±28.2 55.5±26.8† 47.1±26.6 0.016
  Mean gradient, mm Hg 43.1±16.2 39.8±16.0 44.2±17.4 38.2±15.4 0.08
Systemic vascular load
  Systolic arterial pressure, mm Hg 133.8±25.7 125.8±23.6 138.6±30.7 135.6±27.4 0.023
  Diastolic arterial pressure, mm Hg 61.8±12.4 63.0±12.1 66.6±14.2† 71.4±14.3‡ <0.001
  Mean arterial pressure 90.2±16.5 88.6±14.8 95.5±18.8† 97.9±16.9‡ 0.003
  Systemic vascular resistance, mm Hg/min per L 1805±543 1942±714 1938±644 2264±769‡ 0.001
LV systolic function
  Ejection fraction, % 58.5±13.3 54.7±13.4 51.3±15.3† 43.7±16.1‡ <0.001
  LV systolic pressure, mm Hg 183.5±31.4 171.5±33.3* 194.1±35.7† 186.4±31.3 <0.001
  LV end diastolic pressure, mm Hg 17.0±6.7 11.2±2.8* 26.0±6.4† 21.9±4.7‡ <0.001
  Stroke volume, mL 54.7±14.4 46.0±14.5* 50.7±15.3† 38.8±13.7‡ <0.001
  Stroke volume index, mL/m2 30.5±7.2 25.6±7.3* 28.4±7.8† 21.9±7.2‡ <0.001
  Cardiac output, L/min 4.0±0.9 3.6±1.0* 3.8±1.0 3.3±1.2‡ 0.001
  Cardiac index, L/min m² 2.3±0.4 2.0±0.5* 2.1±0.5 1.9±0.6‡ <0.001
  Heart rate, bpm 74.7±10.7 80.8±15.8* 77.7±13.4 89.5±22.2‡ <0.001
Right sided hemodynamics
  PA systolic pressure, mm Hg 32.2±5.8 51.5±11.6* 56.1±12.1† 73.9±16.3‡ <0.001
  PA systolic pressure ≥60 mm Hg, n (%) 0 (0%) 14 (25%)* 75 (34%)† 40 (82%)‡ <0.001
  PA diastolic pressure, mm Hg 10.5±4.0 19.6±5.6* 22.3±6.0† 33.6±5.8‡ <0.001
  Mean PA pressure, mm Hg 18.9±4.3 33.1±6.7* 36.4±7.6† 50.1±7.9‡ <0.001
  Pulmonary arterial compliance, mL/mm Hg 1.5±0.5 0.9±0.3* 0.9±0.4† 0.6±0.3‡ <0.001
  Diastolic pulmonary gradient, mm Hg −6.3±7.5 8.4±6.9* -3.7±6.2† 11.6±4.9‡ <0.001
  Transpulmonic gradient, mm Hg 2.1±7.5 21.9±7.8* 10.3±7.9† 28.3±7.6‡ <0.001
  Pulmonary vascular resistance, dynes s per cm5 45.7±160.0 539.5±281.1* 246.6±206.9† 745.2±292.6‡ <0.001
  Pulmonary vascular resistance, Wood units 0.6±2.0 6.7±3.5* 3.1±2.6† 9.3±3.7‡ <0.001
  RV systolic pressure, mm Hg 33.8±7.0 49.1±13.8* 54.9±11.9† 72.2±16.7‡ <0.001
  RV diastolic pressure, mm Hg 6.0±3.4 8.3±4.9* 11.1±4.9† 14.8±5.2‡ <0.001
  RA mean pressure, mm Hg 4.5±3.5 8.3±5.2* 8.6±4.4† 12.0±4.9‡ <0.001
  Right ventricular stroke work index, g m per m2 per beat  6.0±2.2  8.6±3.3*  10.4±3.3† 11.4±5.0 ‡  <0.001
Depicted are mean±SD with P values from ANOVAs. LV indicates left ventricle; PA, pulmonary artery; PH, pulmonary hypertension; RA, right atrial; and RV, right 
ventricle.
*P<0.05, no PH vs precapillary PH.
†P<0.05, no PH vs isolated PH.
‡P<0.05, no PH vs combined PH.
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undergoing TAVI had PH based on preprocedural invasive 
hemodynamic evaluations and almost one third had severe PH 
(invasive PASP, ≥60 mm Hg).
Several studies have demonstrated that PH affects out-
comes in patients with severe AS independent of the treatment 
modality. Malouf et al2 reported that patients with severe PH 
and AS had a poor prognosis when treated conservatively but 
had a high perioperative mortality with conventional SAVR. 
Similarly, Melby et al31 reported that operative mortality was 
nearly doubled in patients undergoing conventional SAVR in 
the presence of PH and that PH resulted in a decreased long-
term survival. A PASP of >60 mm Hg has been described as a 
strong independent predictor of both in-hospital and long-term 
mortality among patients undergoing SAVR.32 Among TAVI 
patients, previous studies reported PH to be an independent 
predictor of late, rather than early, mortality after the proce-
dure.7,8 Tamburino et al7 reported that PASP >60 mm Hg was 
an independent predictor of overall, but not early, mortality 
among patients with severe AS undergoing TAVI. Similarly, 
in a subanalysis of the French Aortic National CoreValve 
and Edwards (FRANCE 2) Registry (n=2435), Lucon et al8 
observed no significant effect of PH severity on 30-day mor-
tality, but severe PH (PASP, >60 mm Hg) was an independent 
predictor of 1-year mortality.
Concordant with these previous findings, PH was associ-
ated with worse clinical outcomes at 1 year in our study when 
compared with patients without PH. However, PH hemody-
namic presentation is heterogeneous with various underlying 
Table 5. Unadjusted Clinical Outcomes at 1 y
Reference 
No PH 
n=108
PH Precapillary vs No PH Isolated vs No PH Combined vs No PH
Precap 
n=56
Isolated 
n=220
Combined 
n=49 HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
1-y Follow-Up
  All-cause death, n (%) 11 (10.3) 12 (21.7) 37 (17.1) 14 (29.0) 2.30 (1.02–5.22) 0.046 1.73 (0.88–3.39) 0.11 3.15 (1.43–6.93) 0.004
   Cardiovascular death, 
n (%)
7 (6.7) 10 (18.2) 23 (10.8) 11 (23.6) 3.00 (1.14–7.88) 0.026 1.68 (0.72–3.92) 0.23 3.84 (1.49–9.91) 0.005
  Cerebrovascular events 7 (6.6) 4 (7.8) 7 (3.3) 4 (8.2) 1.13 (0.33–3.87) 0.84 0.50 (0.17–1.42) 0.19 1.33 (0.39–4.54) 0.65
   Major stroke, n (%) 4 (3.7) 4 (7.8) 6 (2.8) 4 (8.2) 1.98 (0.49–7.90) 0.34 0.74 (0.21–2.64) 0.65 2.31 (0.58–9.22) 0.24
   Minor stroke, n (%) 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0) … … … … … …
   Transient ischemic 
attack, n (%)
3 (3.0) 0 (0.0) 0 (0.0) 0 (0.0) … … … … … …
  Myocardial infarction, 
n (%)
2 (2.0) 0 (0.0) 4 (1.9) 2 (4.5) … … … … … …
  All-cause death or major 
stroke, n (%)
13 (12.1) 14 (25.3) 41 (18.9) 15 (31.0) 2.24 (1.05–4.76) 0.037 1.61 (0.86–3.01) 0.13 2.86 (1.36–6.01) 0.006
  All-cause death, major 
stroke, or MI, n (%)
15 (14.0) 14 (25.3) 42 (19.3) 16 (33.1) 1.92 (0.93–3.98) 0.08 1.42 (0.79–2.57) 0.24 2.65 (1.31–5.36) 0.007
Depicted are counts (incidence rates, %). HRs (95% [CI]) are from Cox Regressions. CI indicates confidence interval; HR, hazard ratio; MI, myocardial infarction; and 
PH, pulmonary hypertension.
Table 4. Procedural Characteristics
No PH 
n=108
PH
P Value
Precapillary  
n=56
Isolated 
n=220
Combined 
n=49
Access route
  Femoral, n (%) 83 (77) 47 (84) 182 (83) 37 (76) 0.27
  Apical, n (%) 25 (23) 9 (16) 33 (15) 11 (22)
  Subclavian, n (%) 0 (0) 0 (0) 5 (2) 1 (2)
Valve type
  Medtronic CoreValve, n (%) 53 (49) 30 (54) 120 (55) 31 (63) 0.10
  Edwards Sapien valve, n (%) 54 (50) 23 (41) 98 (45) 16 (33)
  Symetis valve, n (%) 1 (1) 3 (5) 2 (1) 2 (4)
Procedural specifications
  Device success, n (%) 100 (93) 45 (82) 186 (86) 42 (86) 0.17
  No device success; AR ≥2+, n (%) 8 (7) 10 (18) 26 (12) 6 (12) 0.25
Depicted are counts (%) with P values from Fisher exact tests. No pairwise comparison (no PH vs precapillary PH, no PH 
vs isolated PH, and no PH vs combined PH) was significant at α of 0.05. AR indicates aortic regurgitation; and PH, pulmonary 
hypertension.
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pathophysiological mechanisms. In general, based on the 
proceedings of the 5th World Symposium on PH in Nice, 
2013, 3 hemodynamic presentations of PH are recognized: 
precapillary, isolated postcapillary, and combined postcap-
illary and precapillary PH (Figure 1), and this replaces the 
older PH classification, which was based on the proceedings 
of the 4th World Symposium on PH (Figure I in the Data 
Supplement).14,15 Either the LVEDP or pulmonary arterial 
wedge pressure can be used for hemodynamic stratification of 
PH and the use of either variable did not substantially change 
the group classification in this study (Table IV in the Data 
Supplement).13 This study is the first to assess the effect of PH 
hemodynamic presentation on clinical outcomes after TAVI 
using the updated invasive definitions.
Postcapillary PH
Postcapillary or left-sided PH is the most common form of 
PH in Western countries.33 In this study, postcapillary PH 
accounted for the vast majority (82%) of PH among patients 
with symptomatic severe AS undergoing TAVI and was 
mostly comprised of isolated postcapillary PH. Left-sided PH 
was observed to have markedly different long-term prognostic 
implications after TAVI depending on whether the DPD was 
normal (ie, isolated postcapillary) or elevated (ie, combined 
postcapillary and precapillary). Patients with combined PH 
had significantly worse 1-year outcomes. Patients with com-
bined PH were observed to have a more insidious form of PH 
on RHC when compared with patients with isolated PH. PH 
severity was worse among patients with combined PH leading 
to a more impaired right ventricular function when compared 
with patients with isolated PH. In addition, pulmonary vas-
cular resistance was elevated suggesting intrinsic changes in 
the pulmonary vascular bed. By definition, all patients with 
combined PH had a DPD of ≥7 mm Hg, which has previously 
been shown to be associated with more advanced pulmonary 
vascular remodeling.19 Conversely, in isolated postcapillary 
PH, the elevation of PASP is thought to be solely due to the 
passive backward transmission of an increased LV filling 
pressure (LVEDP, ≥15 mm Hg). The hemodynamic character-
istics of patients with isolated PH in this study support this 
hypothesis, with patients with isolated PH having near normal 
PVR values. Isolated postcapillary PH is considered revers-
ible, and this may explain why clinical outcomes of patients 
with isolated PH were similar to patients without PH after 
TAVI. In patients with severe AS and LV hypertrophy, it may 
be expected that diastolic LV dysfunction persists after TAVI, 
causing persistent postcapillary PH in the majority of patients 
and this could be prognostically relevant. Further studies are 
needed to assess whether diastolic dysfunction after TAVI is 
related to persistence of postcapillary PH.
Precapillary PH
Precapillary PH is less common than postcapillary PH but is 
a far more heterogeneous entity.14 In our study, it accounted 
for less than one fifth of PH among patients with symptom-
atic severe AS undergoing TAVI but was associated with 
worse clinical outcomes and less functional improvement at 
1 year when compared with patients without PH. The rela-
tive number of patients classified as precapillary PH in the 
present analysis seems to be surprisingly high (13%), as most 
Table 6. Adjusted Clinical Outcomes at 1 y
Precapillary vs No PH Isolated vs No PH Combined vs No PH
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
1-y Follow-Up
  All-cause death, n (%) 1.90 (0.83–4.35) 0.13 1.75 (0.88–3.49) 0.11 3.28 (1.43–7.53) 0.005
   Cardiovascular death, n (%) 2.25 (0.85–5.97) 0.11 1.55 (0.65–3.71) 0.33 3.81 (1.40–10.36) 0.009
  All-cause death or major stroke, n (%) 1.94 (0.90–4.18) 0.09 1.67 (0.88–3.15) 0.12 3.10 (1.41–6.79) 0.005
  All-cause death, major stroke, or MI, n (%) 1.74 (0.83–3.65) 0.14 1.52 (0.83–2.79) 0.17 3.13 (1.49–6.58) 0.003
Depicted are counts (incidence rates, %). Adjusted HRs (95% [CI]) are from multivariable Cox regressions, adjusting for age, sex, diabetes mellitus, 
body mass index, previous coronary artery bypass grafting, previous myocardial infarction, peripheral vascular disease, coronary artery disease, left 
ventricular ejection fraction ≤30%, chronic obstructive pulmonary disease known to be associated with these adverse outcomes. CI indicates confidence 
interval; HR, hazard ratio; MI, myocardial infarction; and PH, pulmonary hypertension.
Table 7. Changes in Left and Right Ventricular Function and Pulmonary Artery Systolic Pressure After Transcatheter Aortic Valve 
Implantation
No Pulmonary Hypertension
Pulmonary Hypertension
Precapillary Isolated Combined
Baseline Discharge P Value Baseline Discharge P Value Baseline Discharge P Value Baseline Discharge P Value
LVEF, % 56.8±13.2 57.5±9.5 0.82 54.9±13.2 54.8±12.9 0.46 51.3±15.5 54.3±13.0 <0.001 44.1±16.1 48.5±14.9 0.008
TAPSE, mm 19.2±4.6 20.2±5.3 0.37 16.1±4.8 18.2±6.1 0.11 19.0±5.7 20.7±6.4 0.060 15.7±4.7 18.5±4.9 0.056
DTI, cm/s 12.2±2.8 13.8±4.1 0.006 11.2±4.4 12.3±2.2 0.39 11.8±2.7 13.7±3.6 <0.001 10.3±2.9 12.0±2.8 0.024
PASP, mm Hg 39.0±10.9 38.1±9.6 0.61 49.0±12.6 51.6±14.3 0.36 50.2±13.7 44.9±14.3 0.001 57.8±14.1 50.4±17.3 0.015
Depicted are crude mean±SD with P values from a linear mixed model taking into account the within-patient correlation (random intercept). Eight patients who died 
in hospital (before discharge) are excluded from the model. DTI indicates pulse Doppler peak velocity at the annulus; LVEF, left ventricular ejection fraction; PASP, 
pulmonary artery systolic pressure; and TAPSE, tricuspid annular plane systolic excursion.
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patients would be expected to have postcapillary PH. How-
ever, Kaple et al33 reported in an entirely separate cohort of 
patients, a similar proportion of patients (20/168; 12%) with 
severe AS undergoing TAVI to have precapillary (pulmonary 
arterial wedge pressure, <15 mm Hg; mPAP, ≥25 mm Hg) PH 
on invasive hemodynamic evaluation. It should be noted that 
left heart disease (and not pulmonary vascular disease) may 
still be the reason for PH even if the LVEDP/pulmonary arte-
rial wedge pressure is <15 mm Hg, particularly in patients 
pretreated with diuretics. However, no significant differences 
in the proportion of patients taking diuretics were observed 
between groups (Table 1). Furthermore, patients with pre-
capillary PH had entirely different echocardiographic and 
invasive hemodynamic characteristics when compared with 
patients with postcapillary PH. For example, patients with 
precapillary PH had a less severe form of AS and better LV 
systolic function when compared with patients with postcapil-
lary PH. Conversely, patients with precapillary PH had similar 
degrees of RV dysfunction when compared with patients with 
combined PH and a higher prevalence of moderate to severe 
tricuspid regurgitation when compared with all other groups. 
Furthermore, patients with precapillary PH had lower PA 
pressures but higher PVR values when compared with patients 
with isolated PH, suggesting that this group is a bona fide dis-
crete entity. Moreover, PASPs and RV function improved in 
both postcapillary groups, but not in the precapillary group, 
further supporting the hypothesis that PH was not because of 
left-sided heart disease among this patient cohort.
Clinical Implications
This study suggests that the stratification of PH according 
to the hemodynamic presentation is useful for risk stratifica-
tion of patients with severe AS being considered for TAVI. 
Determination of the DPD among patients with severe AS 
and left-sided PH predicts long-term outcomes after TAVI. 
Furthermore, hemodynamic stratification of PH also predicts 
Figure 4. Kaplan–Meier analysis of death (A) and cardiovascular death (B) at 1 year comparing patients with isolated postcapillary pul-
monary hypertension (PH), combined postcapillary and precapillary PH, and precapillary PH with patients without PH. CI indicates confi-
dence interval; HR, hazard ratio; and TAVI; transcatheter aortic valve implantation.
Figure 3. Kaplan–Meier analysis of death (A) and cardiovascular death (B) at 1 year among patients with and without pulmonary hyperten-
sion (PH; invasive mean pulmonary artery pressure ≥25 mm Hg) at baseline. CI indicates confidence interval; HR, hazard ratio; and TAVI; 
transcatheter aortic valve implantation.
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response to treatment. In contrast to patients with postcapil-
lary PH, neither RV function nor PASP improved after TAVI 
in patients with precapillary PH, and functional improvement 
was less at 1-year follow-up. Whether a more tailored therapy 
with pulmonary vasodilator therapy (eg, Bosentan, Epopros-
tenol, or Sildenafil) would benefit patients with precapillary 
PH after TAVI is unknown. This study also raises questions on 
the most appropriate management of patients with combined 
postcapillary and precapillary PH. Currently, the mainstay 
of treatment for left-sided PH is treatment of the underlying 
cause. However, in this study, we observed worse outcomes 
among patients with combined PH after TAVI. Whether more 
targeted therapy with pulmonary vasodilator therapies, such 
as phosphodiesterase-5 inhibitors, would improve outcomes 
among patients with combined PH remains unknown.34
Limitations
First, this is a single-center observational study and therefore 
may not reflect general practice. However, all data were col-
lected prospectively and all events were adjudicated by a clini-
cal event committee comprising interventional cardiologists 
and cardiac surgeons. Second, only patients with preproce-
dural RHC were included in this study, and therefore, this is 
not a consecutive patient series. Therefore, the true prevalence 
of PH in severe AS may have been overestimated because 
the inclusion of only patients with preprocedural RHC may 
have led to an enrichment of patients with PH. However, the 
majority of patients (71%) undergoing TAVI during the inclu-
sion period were included. Third, invasive PAPs were only 
measured before TAVI but not afterward. Therefore, changes 
in PASPs before and after TAVI were measured noninvasively 
using echocardiography, which would not be expected to be as 
accurate as invasive measurements. Fourth, echocardiographic 
follow-up beyond discharge is not reported, therefore preclud-
ing PASP and right ventricular function assessment during lon-
ger term follow-up. Fifth, there are limitations involved with 
using estimated, rather than direct, oxygen consumption for 
the calculation of CO as previously described in detail.16 Sixth, 
in places where each of precapillary, isolated, and combined 
PH are compared against no PH, one should strictly declare 
statistical significance if P<0.05/3=0.017, but in this study, we 
used P<0.05 to declare statistical significance. Only pairwise 
comparisons were performed in this study with no PH being 
the reference group. In addition, all significant P values for no 
PH versus combined PH were P<0.017 in both the unadjusted 
(Table 5) and adjusted (Table 6) analyses, and therefore this 
would not have substantially changed the main findings of this 
study. In addition, the P values for no PH versus isolated PH 
were not significant regardless of whether P<0.05 or P<0.017 
was used. Only the unadjusted clinical outcomes of no PH 
versus precapillary PH may have been affected by using 
P<0.05 instead of P<0.017. However, in the adjusted analy-
sis, no PH versus precapillary PH was no longer significant 
for differences in all-cause mortality and cardiovascular death 
Figure 5. Functional status expressed by the New 
York Heart Association (NYHA) classification at 
baseline and 1 year follow-up among patients with 
severe aortic stenosis and isolated postcapillary 
pulmonary hypertension (PH), combined postcapil-
lary and precapillary PH, precapillary PH, and no 
PH.
Figure 6. Changes in right ventricular systolic function (pulsed Doppler peak velocity [DTI] at the annulus; A) and pulmonary artery sys-
tolic pressure (PASP; B) measured noninvasively before and after transcatheter aortic valve implantation (TAVI) among patients with pul-
monary hypertension. Data taken from Table 7.
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(P>0.05), and therefore, the main findings remain unaffected. 
Finally, a fluid challenge was not performed in patients with a 
low LVEDP, which may have unmasked patients with occult 
postcapillary PH. However, Hoeper et al35 have stated that this 
technique requires meticulous evaluation and standardization 
before its use in clinical practice can be recommended.
Conclusions
PH is present in the majority of patients undergoing TAVI in 
the current era and is comprised predominantly of postcapil-
lary PH. Invasive stratification of PH according to hemody-
namic presentation predicts the acute response to therapy and 
1-year mortality after TAVI.
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